Targeted RFA 2018

Movember Translation Acceleration Grant to Validate Predictive Markers for Treatment Response and Outcome

Prostate Cancer Canada (PCC) invites applications for investigator-initiated Movember Translation Acceleration Grants (TAG).

With more treatments coming on line, there is a greater need to assess who will benefit most from each treatment. Projects funded by this TAG mechanism will validate existing putative markers or tests in patient samples, either retrospectively or within a clinical trial. Assays can be biospecimen or imaging markers or other appropriate tests including histology or bioinformatics.

This request for applications (RFA) solicits proposals from groups developing and validating methods to specifically and accurately predict treatment response and/or patient outcome using an appropriate assay. The end goal is clinical validation of the approach and more accurate and personalized selection of treatments for patients with prostate cancer.

It is expected that a multidisciplinary approach will be required and each Movember TAG application may consist of independent investigators based in multiple institutions. PCC also strongly encourages, wherever possible, that applications would access and use existing banked clinical specimens. PCC will only consider projects that are completely focused on prostate cancer.

This opportunity is awarded by Prostate Cancer Canada and proudly funded by the Movember Foundation.

Award amount: up to $1.5M over 3 years
 smaller-still-(1).jpg
Key dates:
Registration Deadline: May 15, 2018
Full Application Deadline: July 9, 2018
Funding start date: October 1, 2018

Links to:
Online application: https://pccgrants.smartsimple.ca
Program Description
Tipsheet
 

Donate Now!

Go Plaid. Help Dad.


Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Dream car draw a win for all Ontarians affected by prostate cancer

February 22, 2019 – TORONTO, ON – A dream came true today for Harold Mutter (ticket #19273), the lucky winner of a 2018 Acura NSX valued at more than $235,000 - the prize for Prostate Cancer Canada’s seventh Rock the Road Raffle.
More

Researchers discover common markers of tumour hypoxia across 19 cancer types

Landmark pan-cancer study analyzes mutation signatures of low oxygen in more than 8,000 tumours
More

Rock the Road Raffle returns with its most valuable car to date

A 2018 Acura NSX to be prized by Prostate Cancer Canada and TADA at the AutoShow  
More


Click here for news archive